Effectiveness of Walking Exercise in Improving Cognitive Function in Older Adults With Mild Cognitive Impairment
NCT04515563, Not applicable, Completed, The University of Hong Kong
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effectiveness of Walking Exercise in Improving Cognitive Function in Older Adults With Mild Cognitive Impairment | ClinicalTrials.gov |
| NCT number | NCT04515563 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 50 participants, actual | ClinicalTrials.gov |
| Lead sponsor | The University of Hong Kong | ClinicalTrials.gov |
| Conditions | Mild Cognitive Impairment | ClinicalTrials.gov |
| Interventions | Stretching exercise, Low-frequency, moderate-intensity walking group, High-frequency, moderate-intensity walking group, Low-frequency, vigorous-intensity walking group, High-frequency, vigorous-intensity walking group | ClinicalTrials.gov |
| First posted | 2020-08-17 | ClinicalTrials.gov |
| Last updated | 2021-11-11 | ClinicalTrials.gov |
Registered outcomes 20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Global cognition-Hong Kong Montreal Cognitive Assessment (HK-MoCA) score | 3-month follow-up | Age- and education-corrected Hong Kong Montreal Cognitive Assessment (HK-MoCA). The HK-MoCA is a validated assessment for cognitive screening that takes into account different domains of cognition, which will enable the researchers to achieve a better understanding of the global cognitive profile of the individual. Higher score indicates better global cognitive performance. | ClinicalTrials.gov |
| Secondary | Objective cognitive score | 3-month follow-up | The NIH Toolbox Cognitive Function Battery (CFB) will be used to evaluate the various cognitive domains \[15\]. CFB will be delivered on a tablet computer. A total objective cognitive score will be generated, while a higher score indicates better cognitive performance. | ClinicalTrials.gov |
| Secondary | Working memory-Digit Span test | 3-month follow-up | Working memory will be measured by Digit Span test in paper-pencil based manner. Higher score indicates better cognitive performance. | ClinicalTrials.gov |
| Secondary | Working memory-Verbal Fluency Test | 3-month follow-up | Verbal Fluency Test will be used to measure working memory. Higher score indicates better cognitive performance. | ClinicalTrials.gov |
| Secondary | Executive function-Stroop test | 3-month follow-up | Executive function will be measured by Stroop test. Shorter completion time indicates better performance. | ClinicalTrials.gov |
| Secondary | Executive function-Trail Making test | 3-month follow-up | Executive function will be measured by Trail Making test. Shorter completion time indicates better performance. | ClinicalTrials.gov |
| Secondary | Subjective cognitive report | 3-month follow-up | Cognitive self-report questionnaire (CSQR) will be used to test the subjective cognitive performance. CSQR is validated in HK and consists of 20 questions with overall score ranging from 0-100. Higher score indicates worse self-perception on cognitive performance. | ClinicalTrials.gov |
| Secondary | Remission rate-Chinese Abbreviated Mild Cognitive Impairment Test (CAMCI) | 3-month follow-up | Chinese Abbreviated Mild Cognitive Impairment Test (CAMCI) will be used to classify participants into MCI and non-MCI category. The remission rate will be calculated as remission rate = number of participants in non-MCI category / number of total participants. | ClinicalTrials.gov |
| Secondary | Remission rate-Hong Kong Montreal Cognitive Assessment (HK-MoCA) | 3-month follow-up | Age- and education-corrected Hong Kong Montreal Cognitive Assessment (HK-MoCA). The HK-MoCA is a validated assessment for cognitive screening that takes into account different domains of cognition, which will enable the researchers to achieve a better understanding of the cognitive profile of the individual. MoCA will be used to classify participants into MCI and non-MCI category. The remission rate will be calculated as remission rate = number of participants in non-MCI category / number of total participants. | ClinicalTrials.gov |
| Secondary | VO2max | 3-month follow-up | A VO2max test will be conducted using a calibrated motor-driven treadmill by continuous metabolic VO2 measurement using a COSMED Quark Series telemetric gas analysis system. The test will be performed using a modified bruce protocol. VO2, Borg's rating of perceived exertion (RPE) and heart rate (HR) will be continuously recorded. The maximal attainable heart rate will be recorded as the peak heart rate (HRpeak). | ClinicalTrials.gov |
| Secondary | Body fat mass | 3-month follow-up | Body fat mass of participants will be measured by dual-energy X-ray absorptiometry (DXA). | ClinicalTrials.gov |
| Secondary | Lean mass | 3-month follow-up | Lean mass of participants will be measured by dual-energy X-ray absorptiometry (DXA). | ClinicalTrials.gov |
| Secondary | Bone mineral density | 3-month follow-up | Bone mineral density of participants will be measured by dual-energy X-ray absorptiometry (DXA). | ClinicalTrials.gov |
| Secondary | Habitual sleep | 3-month follow-up | The Pittsburgh Sleep Quality Index (PSQI) is a standardized instrument to estimate sleep quantity and quality. The PSQI has been commonly used to distinguish people with primary insomnia from normal sleepers. The Chinese version of PSQI has been validated to have a satisfactory Cronbach's alpha of 0.82-0.83 and test-retest reliability of 0.85 among Hong Kong Chinese older adults. The overall score ranges from 0 to 24 while a higher score indicates worse sleep quality. | ClinicalTrials.gov |
| Secondary | Quality of Life-12-item Short Form Survey (SF-12) | 3-month follow-up | The 12-item Short Form Survey (SF-12) will be used to assess the quality of life of the participant and higher scores (physical and mental sub-scale) indicate better quality of life. | ClinicalTrials.gov |
| Secondary | Depression level | 3-month follow-up | Patient Health Questionnaire-9 (PHQ-9) will also be used to assess the mental health of the subjects. A PHQ-9 score of ≥ 10 has a sensitivity of 88% and a specificity of 88% for major depression. PHQ-9 scores of 5, 10, 15, and 20 correspond to mild, moderate, moderately severe, and severe depression, respectively. Results are similar in the primary care and obstetrics-gynecology samples. The PHQ-9 is a reliable and valid measure of depression severity and its brevity make the PHQ-9 a useful clinical and research tool. | ClinicalTrials.gov |
| Secondary | Mental health | 3-month follow-up | Hospital Anxiety and Depression Scale (HADS) will used to measure the mental health of participants. It is a 7-item questionnaire having an overall score that ranges from 0 to 21 (with sub-scales for both anxiety and depression), with a higher score indicating more severe symptoms. | ClinicalTrials.gov |
| Secondary | Anxiety level | 3-month follow-up | Generalized Anxiety Disorder 7-item (GAD-7) scale will be used to measure the anxiety level of participants. It is a 7-item questionnaire having an overall score that ranges from 0 to 21 with a higher score indicating more severe symptoms. | ClinicalTrials.gov |
| Secondary | Physical activity | 3-month follow-up | The International Physical Activity Questionnaire (IPAQ) will be used to assess the activity level of the subjects. | ClinicalTrials.gov |
| Secondary | Balance performance | 3-month follow-up | The balance ability of the subjects will be measured by single leg standing test. The longer standing duration indicates better balance performance. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 36200056 | DERIVED | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)